Direct treatment costs of HIV/AIDS in Portugal / Custos diretos com tratamento do VIH/SIDA em Portugal / Costos originados por tratamiento del VIH/SIDA en Portugal

OBJECTIVE To analyze the direct medical costs of HIV/AIDS in Portugal from the perspective of the National Health Service. METHODS A retrospective analysis of medical records was conducted for 150 patients from five specialized centers in Portugal in 2008. Data on utilization of medical resources during 12 months and patients’ characteristics were collected. A unit cost was applied to each care component using official sources and accounting data from National Health Service hospitals. RESULTS The average cost of treatment was 14,277 €/patient/year. The main cost-driver was antiretroviral treatment (€ 9,598), followed by hospitalization costs (€ 1,323). Treatment costs increased with the severity of disease from € 11,901 (> 500 CD4 cells/µl) to € 23,351 (CD4 count ≤ 50 cells/ µl). Cost progression was mainly due to the increase in hospitalization costs, while antiretroviral treatment costs remained stable over disease stages. CONCLUSIONS The high burden related to antiretroviral treatment is counterbalanced by relatively low hospitalization costs, which, however, increase with severity of disease. The relatively modest progression of total costs highlights that alternative public health strategies that do not affect transmission of disease may only have a limited impact on expenditure, since treatment costs are largely dominated by constant antiretroviral treatment costs. .

OBJETIVO Analizar los costos médicos originados por tratamiento de VIH/SIDA, de acuerdo con la perspectiva del Servicio Nacional de Salud, en Portugal. MÉTODOS Se realizó análisis retrospectivo de registros médicos en muestra de 150 pacientes de cinco centros especializados, en 2008. Se obtuvieron datos de utilización de recursos médicos y de las características de los pacientes, en horizonte temporal de 12 meses. Se aplicó el costo unitario a cada componente de costo, usando fuentes oficiales y datos de contabilidad de los hospitales. RESULTADOS El costo promedio anual del tratamiento fue de 14,277€ por paciente. La parcela de costo más importante fue el relacionado con el tratamiento antiretrovial (9,598€), seguido por los costos de internación (1,323€). Los costos de tratamiento con severidad aumentaron de 11,901€ (> 500 CD4 células/µl) para 23,351€ (CD4 ≤ 50 células/µl). La progresión de los costos se debe mayormente al aumento de los costos de internación, dado que los costos por tratamiento antiretrovial se mantienen constantes a lo largo de las fases. CONCLUSIONES El elevado costo del tratamiento antiretrovial es compensado por el costo relativamente bajo de la internación, a pesar de que éste aumenta con la severidad. La baja progresión de los costos totales revela que estrategias de salud pública alternativas que no alteren la transmisión de la enfermedad tendrán sólo impacto limitado en los gastos, dado que los costos son mayormente influenciados por el tratamiento antiretrovial. .

OBJETIVO Analisar dos custos diretos médicos com VIH/SIDA, de acordo com a perspetiva do Serviço Nacional de Saúde, em Portugal. MÉTODOS Efetuou-se análise retrospectiva de registros médicos em amostra de 150 pacientes de cinco centros especializados em 2008. Foram obtidos dados de utilização de recursos médicos durante 12 meses e das características dos pacientes nesse período. Aplicou-se o custo unitário a cada componente de custo, usando fontes oficiais e dados contabilísticos dos hospitais. RESULTADOS O custo médio anual de tratamento foi de 14.277 euros por paciente. A parcela de custo mais importante foi o custo com o tratamento antirretroviral (9.598 euros), seguido dos custos de internação (1.323 euros). Os custos de tratamento com severidade aumentaram de 11.901 euros (> 500 CD4 células/µl) para 23.351 euros (CD4 ≤ 50 células/µl). A progressão dos custos deve-se principalmente ao aumento dos custos de internação, dado que os custos com tratamento antirretroviral se mantêm constantes ao longo dos estádios. CONCLUSÕES O custo elevado do tratamento antirretroviral é compensado com o custo relativamente baixo da internação, apesar deste aumentar com a severidade. A baixa progressão dos custos totais revela que estratégias de saúde pública alternativas que não alterem a transmissão da doença terão apenas impacto limitado nas despesas, dado que os custos são largamente influenciados pelo do tratamento antirretroviral. .

Direct treatment costs of HIV/AIDS in Portugal.

OBJECTIVE: To analyze the direct medical costs of HIV/AIDS in Portugal from the perspective of the National Health Service. METHODS: A retrospective analysis of medical records was conducted for 150 patients from five specialized centers in Portugal in 2008. Data on utilization of medical resources during 12 months and patients' characteristics were collected. A unit cost was applied to each care component using official sources and accounting data from National Health Service hospitals. RESULTS: The average cost of treatment was 14,277 €/patient/year. The main cost-driver was antiretroviral treatment (€ 9,598), followed by hospitalization costs (€ 1,323). Treatment costs increased with the severity of disease from € 11,901 (> 500 CD4 cells/µl) to € 23,351 (CD4 count ≤ 50 cells/ µl). Cost progression was mainly due to the increase in hospitalization costs, while antiretroviral treatment costs remained stable over disease stages. CONCLUSIONS: The high burden related to antiretroviral treatment is counterbalanced by relatively low hospitalization costs, which, however, increase with severity of disease. The relatively modest progression of total costs highlights that alternative public health strategies that do not affect transmission of disease may only have a limited impact on expenditure, since treatment costs are largely dominated by constant antiretroviral treatment costs.

Gender disparities in health and healthcare: results from the Portuguese National Health Interview Survey / Disparidades de gênero na saúde e nos cuidados de saúde: resultados para Portugal com base no Inquérito Nacional de Saúde

Although women experience poorer health conditions during their lives, they live longer than men. The main explanations for this paradox suggest that women's excess of ill-health is limited to minor illnesses and their different attitudes toward health. The authors test these assumptions by investigating disparities between men and women in health and healthcare in Portugal. Data are used from the Portuguese National Health Interview Survey 2005/2006 (N = 33,662). Multivariate regressions showed that women were more likely to report worse self-rated health, more days with disability, higher prevalence of hypertension, chronic pain, cancer, anxiety and depression, and more medical consultations. Heart disease was significantly more prevalent among men, possibly explaining part of the paradox. Women's more frequent use of medical consultations may reflect their heightened awareness of health problems, which may protect them against early death. Gender differences in socioeconomic status explain part of the differences in health, but fail to provide a complete understanding.

Embora tenham pior saúde ao longo da vida, as mulheres vivem mais anos do que os homens. As principais explicações para este paradoxo são que as mulheres sofrem mais de doenças menores, e adotam atitudes diferentes em relação à saúde. Testamos essas hipóteses pela investigação de disparidades entre homens e mulheres na saúde e nos cuidados de saúde em Portugal. Os dados usados são do Inquérito Nacional de Saúde 2005/2006 (N = 33.662). Regressões multivariadas mostram que as mulheres declaram pior estado de saúde autoavaliado, maior número de dias de incapacidade, maior prevalência de hipertensão, dor crônica, cancro, ansiedade e depressão, e maior utilização de consultas. A doença cardíaca é significativamente mais prevalente nos homens, o que pode explicar em parte o paradoxo. A maior utilização de consultas nas mulheres pode refletir a sua maior consciência relacionada com a saúde, que talvez seja protetora contra a morte precoce. Diferenças de gênero no estatuto socioeconômico explicam parte das diferenças em saúde, mas não permitem uma compreensão completa das diferenças.

Gender disparities in health and healthcare: results from the Portuguese National Health Interview Survey.

Although women experience poorer health conditions during their lives, they live longer than men. The main explanations for this paradox suggest that women's excess of ill-health is limited to minor illnesses and their different attitudes toward health. The authors test these assumptions by investigating disparities between men and women in health and healthcare in Portugal. Data are used from the Portuguese National Health Interview Survey 2005/2006 (N = 33,662). Multivariate regressions showed that women were more likely to report worse self-rated health, more days with disability, higher prevalence of hypertension, chronic pain, cancer, anxiety and depression, and more medical consultations. Heart disease was significantly more prevalent among men, possibly explaining part of the paradox. Women's more frequent use of medical consultations may reflect their heightened awareness of health problems, which may protect them against early death. Gender differences in socioeconomic status explain part of the differences in health, but fail to provide a complete understanding.